Company profile

Future of BioMarin Pharmaceutical

#
Rank
587
| Quantumrun Global 1000

BioMarin Pharmaceutical Inc. is a US-based biotechnology firm involved in enzyme replacement therapies (ERTs) as its core business and research. BioMarin was the first company which provided therapeutics for phenylketonuria (PKU). It was also the first company which provided therapeutics for mucopolysaccharidosis type I (MPS I), by producing laronidase (or Aldurazyme, commercialized by Genzyme Corporation). The company is headquartered in San Rafael, California, with corporate facilities and offices in the United States, South America, Asia, and Europe.

Home Country:
Industry:
Biotechs
Founded:
1985
Global employee count:
2293
Domestic employee count:
Number of domestic locations:
1

Financial Health

Revenue:
$1116854000 USD
3y average revenue:
$918677667 USD
Operating expenses:
$1920283000 USD
3y average expenses:
$1254351667 USD
Funds in reserve:
$408330000 USD
Market country
Revenue from country
0.45
Revenue from country
0.23

Asset Performance

  1. Product/Service/Dept. name
    Vimizim
    Product/Service revenue
    354100000
  2. Product/Service/Dept. name
    Kuvan
    Product/Service revenue
    348000000
  3. Product/Service/Dept. name
    Naglazyme
    Product/Service revenue
    296500000

Innovation assets and Pipeline

Investment into R&D:
$661900000 USD
Total patents held:
66

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.

*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.

*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.

*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.

*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.

*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.

COMPANY’S FUTURE PROSPECTS

Company Headlines